Quantcast

Latest Johnson & Johnson Pharmaceutical Research & Development L.L.C. Stories

2011-08-04 12:30:00

SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today the publication of research that uncovered a previously unknown role for a class of molecules that could lead to future advances in immunologic medicine. The findings show a definitive link between EBI2, a G-protein-coupled receptor that controls B-cell migration, and some unexpected immunological effects of certain oxysterols. Co-authored by the...

2011-07-01 14:00:00

RARITAN, N.J., July 1, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. "The approval of once-daily XARELTO® tablets will provide a new...

2011-06-03 06:30:00

CHICAGO, June 3, 2011 /PRNewswire/ -- Data related to ZYTIGA(TM) (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The studies were sponsored by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc. "We are pleased that these data have been selected for presentation at the 2011 ASCO Annual Meeting," said William N. Hait, M.D., Ph.D., Global Therapeutic Area Head, Ortho Biotech...

2011-04-11 07:00:00

TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of INVEGA® to treat schizophrenia in adolescents was established in one six-week clinical study. INVEGA® is an atypical antipsychotic medication and was first approved in the U.S. in December...

2010-12-01 08:00:00

BEERSE, Belgium, Dec. 1, 2010 /PRNewswire/ -- Janssen Pharmaceutica N.V., (Janssen) today announced a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer's disease prior to the onset of clinical symptoms. Pre-symptomatic biosignatures will allow earlier diagnosis of the disease and may enable significantly earlier intervention in Alzheimer's disease. This collaboration will bring together Janssen's...

2010-11-15 08:00:00

CHICAGO, Nov. 15, 2010 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that results from the pivotal Phase 3 double-blind ROCKET AF trial showed rivaroxaban given once daily was superior in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF) with comparable safety versus warfarin, the most commonly used medicine for the prevention of stroke in AF patients.(1) To view the multimedia...

2010-11-02 07:05:00

TITUSVILLE, N.J., Nov. 2, 2010 /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA® (methylphenidate HCl extended-release tablets). Watson will launch the authorized generic beginning May 1, 2011. "The availability of an authorized generic version of CONCERTA that is both bioequivalent and clinically...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related